ReviewBiomolecules2023
BODIPY-Based Molecules for Biomedical Applications.
Review in Biomolecules, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 62 citations in OpenAlex.
- Solvatochromic diacylglycerol-mimetic probes reveal distinct trafficking of DAG-like lipids to lipid droplets.Bioorganic chemistry · 2026Article
- Free Fatty acid-induced disruption of hepatic vitamin D metabolism impairs bone homeostasis in an in vitro 3D human liver-bone model.Archives of toxicology · 2026Article
- Recent Advances in Organofluoroprobes for Brain Imaging: Progress, Challenges, and Future Directions.ACS pharmacology & translational science · 2026Review
- Photocontrolled immunotherapy: a BODIPY-caged MSA-2 for spatiotemporal activation of STING with visible light.New journal of chemistry = Nouveau journal de chimie · 2026Article
- Utility and Limitations of the Methyl Diaminobenzene-BODIPY Fluorescent Biosensor for Detecting Methylglyoxal in Cells.ACS omega · 2026Article
- A New Class of Anionic Near-Infrared Fluorescent Dyes with 1,6-Diheterophenalene-2,5-dione End Groups.Chemical & biomedical imaging · 2026Article
- Investigation of boron-fluorine bond reactivity inBeilstein journal of organic chemistry · 2026Article
- Acid-Catalyzed Dehydrative Nucleophilic Substitutions of 2,6-Di(hydroxymethyl) BODIPYs: A Platform for BODIPY Functionalization.Organic letters · 2025Article
- A Novel BODIPY-Derived Fluorescent Sensor for Sulfite Monitoring.Sensors (Basel, Switzerland) · 2025Article
- Anionic Boron-Cluster BODIPY Conjugates As Promising Photosensitizers for Targeted Antimicrobial Photodynamic Therapy.ACS omega · 2025Article
- Photophysical Properties and Protein Binding Studies of Piperazine-Substituted Anthracene-BODIPY Dyads for Antimicrobial Photodynamic Therapy.Molecules (Basel, Switzerland) · 2025Article
- Fluoride Ion Selective Multihydroxylated Anthracene Derivatives.ACS omega · 2025Article
- Water-soluble BODIPY dyes: a novel approach for their sustainable chemistry and applied photonics.Chemical science · 2025Article
- Fighting Cancer with Photodynamic Therapy and Nanotechnologies: Current Challenges and Future Directions.International journal of molecular sciences · 2025Review
- A new dawn in research: FDA approves pegulicianine for fluorescence-guided surgery in breast cancer patients.Annals of medicine and surgery (2012) · 2025Article
- The Medical Basis for the Photoluminescence of Indocyanine Green.Molecules (Basel, Switzerland) · 2025Review
- Novel BODIPY Dyes with aBiomedicines · 2025Article
- Enhancing Phototoxicity in BODIPY-Perylene Charge Transfer Dyads by Combined Iodination and Mesylation.Chemistry (Weinheim an der Bergstrasse, Germany) · 2024Article
- Chemistry and properties of fluorescent pyrazole derivatives: an approach to bioimaging applications.RSC advances · 2024Review
- Liposomal Formulations of Novel BODIPY Dimers as Promising Photosensitizers for Antibacterial and Anticancer Treatment.Molecules (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BODIPY (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) derivatives have attracted attention as probes in applications like imaging and sensing due to their unique properties like (1) strong absorption and emission in the visible and near-infrared regions of the electromagnetic spectrum, (2) strong fluorescence and (3) supreme photostability. They have also been employed in areas like photodynamic therapy. Over the last decade, BODIPY-based molecules have even emerged as candidates for cancer treatments. Cancer remains a significant health issue world-wide, necessitating a continuing search for novel therapeutic options. BODIPY is a flexible fluorophore with distinct photophysical characteristics and is a fascinating drug development platform. This review provides a comprehensive overview of the most recent breakthroughs in BODIPY-based small molecules for cancer or disease detection and therapy, including their functional potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.